Histological study of the biodynamics of iron oxide nanoparticles with different diameters

Keiko Tsuchiya1
Norihisa Nitta1
Akinaga Sonoda1
Ayumi Nitta-Seko1
Shinichi Ohta1
Hideji Otani1
Masashi Takahashi1
Kiyoshi Murata1
Katsutoshi Murase2
Satoshi Nohara2
Kenichi Mukaisho3
1Department of radiology, Shiga University of Medical Science, Otsu, Shiga, 2The Nagoya Research Laboratory, Meito Sango Co, Ltd, Kiyosu, Aichi, 3Department of Pathology, Shiga University of Medical Science, Otsu, Shiga, Japan

Abstract: The biodynamics of ultrasmall and small superparamagnetic iron oxide (USPIO and SPIO, respectively) particles that were injected intraperitoneally into 36 C57BL/6 mice were investigated chronologically. Their distribution was studied histologically at six time points by measuring iron-positive areas (µm²) in organ sections stained with Prussian blue. The uptake of the differently sized particles was also compared by cultured murine macrophages (J774.1). Iron-positive areas in the liver were significantly larger in the mice injected with USPIO than those injected with SPIO at the first three time points (P < 0.05). The amount of USPIO in the lung parenchyma around the airway was larger than that of SPIO at four time points (P < 0.05); distribution to the lymph nodes was not significantly different. The amount of iron was significantly larger in SPIO- than USPIO-treated cultured cells (P < 0.05). In conclusion, it is suggested that intra peritoneally injected USPIO particles could be used more quickly than SPIO to make Kupffer images of the liver and that both agents could help get lymph node images of similar quality.

Keywords: USPIO, SPIO, contrast agent, biodistribution, histology

Introduction

The uptake of superparamagnetic iron oxide (SPIO) particles by cells of the mononuclear phagocytic system (MPS) results in hepatic, splenic, bone marrow, and nodal iron accumulation. The selective accumulation of these particles by the MPS is exploited at organ-specific magnetic resonance imaging (MRI). The biodynamics of iron oxide nanoparticles vary depending on particle diameter. Unlike SPIO preparations comprised of large particles and magnetite microspheres (mean particle diameter, 72 nm and 1–5 µm, respectively), ultrasmall superparamagnetic iron oxide (USPIO) particles (mean diameter, 18 nm) are not immediately recognized by the hepatic and splenic MPS. The resultant prolongation of its intravascular half-life, together with its inherent T1 shortening properties, render USPIO a useful magnetic resonance angiography blood-pool agent. In contrast to large-particle superparamagnetic agents, the size of USPIO particles allows the extravasation of USPIO through capillary pores, the diameters of which range from 5 to 100 nm, and this capillary permeability facilitates the uptake of USPIO in MPS cells throughout the body.

Although information on the biodynamics of iron oxide nanoparticles of different diameters is important for various organ-specific MRI studies, to date this issue has not been addressed histologically. Therefore, a comparative histological study of the sequential biodynamics of USPIO and SPIO was performed.
Material and methods
Shiga University of Medical Science’s animal experimentation committee approved all experimental protocols and all experiments were conducted in accordance with the animal care guidelines of the university.

Iron oxide nanoparticles
Two kinds of iron oxide were studied: USPIO (Meito Sangyo Co, Ltd, Kiyosu, Aichi, Japan) and SPIO (Resovist®; Pharmacia Co, Ltd, Shinagawa-ku, Tokyo, Japan). The mean particle diameters and iron concentrations of USPIO and SPIO were 30 nm and 56 mg/mL and 57 nm and 28 mg/mL, respectively. Average diameter of the magnetic core was the same (5 nm) in both particle types. The iron oxide core of both particle types was coated with dextran; their magnetic susceptibility was almost the same (about 0.027 cgs).

In vivo study
USPIO or SPIO was injected intraperitoneally (500 µmol Fe/kg) into 8-week-old female C57BL/6 mice (Japan SLC, Inc, Tokyo, Japan), each weighing approximately 30 g. Groups of three mice each were treated with USPIO or SPIO and sacrificed at time points of 30 minutes and 1, 3, 12, 24, and 48 hours after injection. Organs to be studied were removed for histological study. Sections of the liver at 30 minutes. Iron-positive areas at the hepatic sinusoid corresponding to the area harboring Kupffer cells coincided with macrophage-positive F4/80-stained areas, as shown in Figure 3. 

Wako, Saitama, Japan) was used, which is widely used in research on macrophages. Cells (5 × 10⁴) were seeded in 12-well multiple well culture plates (Costar®; Corning Inc, Corning, NY) and grown at 37°C for 24 hours in 1 mL of growth medium (RPMI-1640; Nacalai Tesque, Inc, Kyoto, Japan) supplemented with 10% (v/v) fetal bovine serum (FBS) (Invitrogen Ltd, Carlsbad, CA) and 1% (w/v) penicillin and streptomycin solution (Nacalai Tesque, Inc). After 24 hours, the medium was replaced, USPIO or SPIO was added (10 µg : 100 µL) and the plates were incubated for 1 hour for cell labeling. After this, the medium was again replaced and the wells then incubated for 24 hours. To identify intracellular iron oxide accumulation, the cells were stained with Prussian blue. The amount of iron contained in cell lysates by atomic absorption photometry (AA-6800; Shimadzu Co, Kyoto, Japan) was measured. Cell labeling was as described in a previous study.¹⁹

Statistical analysis
Statistical analysis was carried out using Dr SPSS II for Windows (SPSS Japan Inc, Tokyo, Japan). Differences in the uptake of USPIO and SPIO in murine tissues and the uptake of iron by cultured cells were determined with the one-tailed Student’s t-test. A P-value < 0.05 was considered statistically significant.

Results
Quantitative histological analysis
Quantitative analysis based on the measurement of Prussian-blue-stained areas revealed that iron-positive areas in the liver were larger in the mice injected with USPIO than those injected with SPIO at almost all time points except the last one (828 vs 0 µm² at 30 minutes, 1299 vs 297 µm² at 1 hour, 3647 vs 853 µm² at 3 hours, 2256 vs 1497 µm² at 12 hours, 1885 vs 1168 µm² at 24 hours, and 1948 vs 2483 µm² at 48 hours), as shown in Figures 1 and 2. The difference was significant at 30 minutes, 1, and 3 hours (P < 0.05). USPIO was quickly distributed throughout the liver; its distribution increased until 3 hours postinjection and decreased thereafter. On the other hand, the distribution of SPIO occurred more slowly and increased over a longer period of time. Unlike USPIO, SPIO was not detected in the liver at 30 minutes. Iron-positive areas at the hepatic sinusoid corresponding to the area harboring Kupffer cells coincided with macrophage-positive F4/80-stained areas, as shown in Figure 3.

In lung specimens, a few USPIO and SPIO particles were observed early; they were located in the parenchyma around
Figure 1 Histological study of mouse liver specimens stained with Prussian blue (magnification ×200). (A), (B), (C): 30 minutes, 1, and 3 hours, respectively, after intraperitoneal (IP) injection of ultrasmall superparamagnetic iron oxide. (D), (E), (F): 30 minutes, 1, and 3 hours, respectively, after IP injection of small superparamagnetic iron oxide.

Figure 2 Comparison of Prussian-blue-stained areas (µm²) in the liver. At 30 minutes, 1, and 3 hours after intraperitoneal injection, iron-positive areas were significantly larger in mice treated with ultrasmall superparamagnetic iron oxide (USPIO) than with small superparamagnetic iron oxide (SPIO).

Note: *P < 0.05.
the airway and their number was increased dramatically at 3 hours postinjection and decreased thereafter, as shown in Figure 4. At all time points, iron positive areas in the lung parenchyma were larger in the mice injected with USPIO than those injected with SPIO (65 vs 29 at 30 minutes, 149 vs 52 at 1 hour, 4812 vs 1364 at 3 hours, 906 vs 201 at 12 hours, 616 vs 167 at 24 hours, and 288 vs 249 at 48 hours), as shown in Figure 5. In addition, at 30 minutes, 1, 3, and 24 hours the iron-positive areas were significantly larger in mice injected with USPIO ($P < 0.05$).

Both USPIO and SPIO were abundant at all time points in mediastinal lymph nodes; there was no difference between the two groups of mice ($P > 0.05$), as shown in Figures 6 and 7. As in liver specimens, iron-positive areas coincided with macrophages in lung and lymph node samples.

Discussion

To our knowledge, this is the first study comparing the biodynamics of intraperitoneally injected USPIO and SPIO. SPIO (Resovist) is the contrast agent used in MRI and generally its safety in the clinical setting has already been established. USPIO used in this study is different in particle size from that of SPIO, but very similar in composition. Ferumoxtran-10, similar to the USPIO used in this study, was well tolerated in phase I and II studies in adult humans.20,21 In addition, in a safety study conducted in adult rabbits, no inflammation or fibrosis occurred after intraperitoneal (IP) injection of

There was no significant accumulation in the heart, great vessels, kidneys, or gastrointestinal tract. As the controls harbored abundant stores of iron, visualized as Prussian-blue-positive areas, macroscopically it was observed that there was almost no difference between them and USPIO- or SPIO-treated mice with respect to the spleen. Control mice manifested no significant iron deposits in organs other than the spleen.

**In vitro study**

While almost all cultured J774.1 cells phagocytized USPIO and SPIO, the amount of intracellular iron measured by atomic absorption photometry was significantly higher in cells treated with SPIO than with USPIO (695 vs 108 pg/cell, $P < 0.05$), as shown in Figure 8.
Figure 5 Comparison of Prussian-blue-stained areas (µm²) in the lung parenchyma. The iron-positive areas were significantly larger in mice intraperitoneally injected with ultrasmall superparamagnetic iron oxide (USPIO) than with small superparamagnetic iron oxide (SPIO) at 30 minutes, 1, 3, and 24 hours. Note: *P < 0.05.

NC100150, a USPIO similar to ferumoxtran-10, IP iron-dextran supplementation is known to be effective and safe in correcting iron deficiency in rats and humans. In our study, IP injection was safe and never caused the death of any mouse.

USPIO was distributed to the liver as early as 30 minutes postinjection; it peaked at 3 hours and decreased thereafter. SPIO appeared later and its distribution throughout the liver increased over time. At 12 hours postinjection, the hepatic distribution of both agents was comparable. A greater amount of USPIO than SPIO tended to be distributed to the lung parenchyma around the airway, possibly because USPIO was presented more easily to the small lymphatic vessels around the airway. There was no significant difference in lymph node accumulation between the two groups of mice.

The early distribution of intraperitoneally injected USPIO to the liver and the absence of significant differences in the lymph node distribution of USPIO and SPIO are primarily attributable to differences in the absorption route. The trapping of intravenously administered USPIO by reticuloendothelial cells in the liver and spleen has...
Figure 6  Prussian-blue staining of mediastinal lymph nodes (magnification ×100). (A), (B): 30 minutes and 1 hour after intraperitoneal (IP) injection of ultrasmall superparamagnetic iron oxide. (C), (D): 30 minutes and 1 hour after IP injection of small superparamagnetic iron oxide.

Figure 7  Comparison of distribution of ultrasmall superparamagnetic iron oxide (USPIO) and small superparamagnetic iron oxide (SPIO) in the lymph nodes. 
Note: P > 0.05 at all time points.
been reported to be difficult because the particle diameter is small and the particles persist in the blood.11,12 Lukas et al25 who studied the absorption route of intraperitoneally administered compounds, suggested that particles absorbed by the subperitoneal capillary system reached the liver via the hepatic portal system. The earlier hepatic distribution of USPIO suggests that it is delivered via this pathway. Intercellular spaces directly open to lymphatic vessels are present in the mesothelial layer of the peritoneum. The peritoneal cavity is the origin of two major lymphatic networks: the thoracic duct drains the retroperitoneal region and enters the left subclavian vein; the right lymphatic duct collects lymph from parasternal and intercostal-paravertebral lymph ducts and drains mainly through the diaphragm and, ultimately, into the right subclavian vein. In the former network, lymph passes through iliac, renal, splenic, posterior gastric, portal, superior mesenteric, and cisternal lymph nodes; in the latter network it passes through more distal (eg, parathymic) and left and right posterior mediastinal lymph nodes.26,27 The authors posited that there was not only USPIO present in abundant amounts in the lymphatic tracts due to these networks but also SPIO, which tended to be trapped in the liver with only slight distribution to the lymph nodes.

Cultured macrophages absorbed SPIO more readily than USPIO. Under conditions where the same number of macrophages respond to iron oxide compounds containing the same amount of iron, larger particles are recognized more easily. This is consistent with the hypothesis that upon intravenous (IV) infusion, reticuloendothelial cells in the liver and spleen trap SPIO more readily than USPIO.

This study had some limitations. First, the number of mice was too small for an accurate elucidation of the pharmacokinetics and prevented the exclusion of interindividual differences. Second, it could not be confirmed that the minute amounts of USPIO and SPIO used were injected accurately into the peritoneal cavity. In some instances, the agent might have been injected subcutaneously or into the bowel. Third, due to technical challenges, the pharmacokinetics of intravenously delivered USPIO or SPIO was not studied. However, considering the mechanisms by which USPIO reached the liver earlier than SPIO and the result that similar amounts of USPIO and SPIO were distributed throughout the lymph nodes, it is important to compare the differences of distribution between USPIO and SPIO via two different injection routes (IP and IV).

The findings suggest that the IP delivery of both USPIO and SPIO might be useful as a contrast agent for the study of lymph nodes in a clinical setting. The IP delivery of USPIO might also be used as a contrast agent for studying the liver. As IP delivery is not a popular injection route in clinical settings, drugs or contrast agents are currently intraperitoneally injected in limited cases of patients with cancer, peritonitis, or chronic renal failure requiring continuous ambulatory peritoneal dialysis (CAPD).24,28–30 Although clinical application is limited, the authors suggest, for cases of patients with ascites of unknown origin, that intraperitoneally injected iron particles may be very useful for getting Kupffer images of the liver and lymph node images to help diagnose metastases in these areas. Also, in cases of iron-deficient CAPD patients, intraperitoneally injected iron dextran has potential for filling both roles, as a route of entry in iron therapy and as a contrast agent for the liver and lymph nodes. In addition, depending on the diameter of the administered particles, it may be possible to deliver agents other than USPIO and SPIO intraperitoneally for the study of various organs.

Conclusion
This study suggests that intraperitoneally injected USPIO could be used more quickly than SPIO can to make Kupffer images of the liver and that both agents could help get lymph node images of similar quality.

Disclosure
The authors report no conflicts of interest in this work.

References
1. Saini S, Stark DD, Hahn PF, Wittenberg J, et al. Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. Radiology. 1987;162(1 Pt 1):211–216.
2. Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol. 1989;152(1):167–173.
3. Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology. 1990;175(2):494–498.
4. Will O, Purkayastha S, Chan C, et al. Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. Lancet Oncol. 2006;7(1):52–60.
5. Sigal R, Vogl T, CasseLMAN J, et al. Lymph node metastases from head and neck squamous cell carcinoma: MR imaging with ultrasmall superparamagnetic iron oxide. J Magn Reson Imaging. 2007;26(1):110–1113.
6. Daldrup HE, Link TM, Blasius S, et al. Monitoring radiation-induced changes in bone marrow histopathology with ultrasmall superparamagnetic iron oxide (USPIO)-enhanced MRI. J Magn Reson Imaging. 1999;9(5):643–652.
7. Senêtèrre E, Weissleder R, Jaramillo D, et al. Bone marrow: ultra-small superparamagnetic iron oxide: preliminary observations. J Comput Assist Tomogr. 2001;25(5):770–776.
8. Weissleder R, Hahn PF, Stark DD, et al. Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging. Radiology. 1988;169(2):399–403.
9. Weissleder R, Stark DD, Elizondo G, et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology. 1988;168(2):297–301.
10. Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology. 1990;175(2):489–493.
11. Vassallo P, Moore HL, Lee JH, et al. Chronic peritoneal dialysis in iron-deficient rats with solutions containing iron dextran. Kidney Int. 2001;59(2):764–773.
12. Reddy DK, Moore HL, Lee JH, et al. Chronic peritoneal dialysis in iron-deficient rats with solutions containing iron dextran. Kidney Int. 1990;178(3):562–564.
13. Anzai Y, Prince MR, Chenevert TL, et al. MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent. J Magn Reson Imaging. 1997;7(1):209–214.
14. Loubeyre P, Zhao S, Canet E, et al. Ultrasmall superparamagnetic iron oxide particles (AMI 227) as a blood pool contrast agent for MR angiography: experimental study in rabbits. J Magn Reson Imaging. 1997;7(6):958–962.
15. Renkin EM. Multiple pathways of capillary permeability. Circ Res. 1977;41(6):735–743.
16. Banerjee S, Narayanan K, Mizutani T, et al. Murine coronavirus replication-induced p38 mitogen-activated protein kinase activation promotes interleukin-6 production and virus replication in cultured cells. J Virol. 2002;76(12):5937–5948.
17. Khoury M, Escriou V, Courties G, et al. Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipopolyses. Arthritis Rheum. 2008;58(8):2356–2367.
18. Taniguichi S, Yanase T, Kobayashi K, et al. Dehydroepiandrosterone markedly inhibits the accumulation of cholesterol ester in mouse macromphage J774–771 cells. Atherosclerosis. 1996;126(1):143–154.
19. Jo J, Aoki I, Tabata Y. Design of iron oxide nanoparticles with different sizes and surface charges for simple and efficient labeling of mesenchymal stem cells. J Control Release. 2010;142(3):465–473.
20. Sharma R, Saini S, Ros PR, et al. Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: phase II clinical trial data. J Magn Reson Imaging. 1999;9(2):291–294.
21. McLaughlin SJ, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging. 1994;4(3):301–307.
22. Hilfiker PR, Debatin JF, Tarlo K, et al. Assessment of peritoneal tolermance of a new MR blood pool contrast agent in rabbits. Invest Radiol. 1999;34(11):722–727.
23. Reddy DK, Moore HL, Lee JH, et al. Chronic peritoneal dialysis in iron-deficient rats with solutions containing iron dextran. Kidney Int. 2001;59(2):764–773.
24. Bastani B, Galley S. Intrapерitoneal iron-dextran as a potential route of iron therapy in CAPD patients. Perit Dial Int. 1996;16(6):646–648.
25. Lukas G, Brindle SD, Greengard P. The route of absorption of intraperitoneally administered compounds. J Pharmacol Exp Ther. 1971;178(3):562–564.
26. Rusznyák L, Földi M, Szabo G. Filtration and absorption through serous membranes. Lymphatics and Lymph Circulation. 2nd ed. Oxford: Pergamon Press; 1967:478–497.
27. Tilney NL. Patterns of lymphatic drainage in the adult laboratory rat. J Anat. 1971;109(Pt 3):369–383.
28. Zylberberg B, Dormont D, Antoine JM, et al. First line immunochemo	herapy with cisplatin-based protocol by intraperitoneal and intravenous routes in ovarian cancer: technique and results of 82 cases. Eur J Obstet Gynecol Reprod Biol. 1996;66(1):57–64.
29. Ruf P, Kluge M, Jäger M, et al. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. Br J Clin Pharmacol. 2010;69(6):617–625.
30. Tamano M, Hashimoto T, Kojima K, et al. Diagnosis of hepatic hydrothomrax using contrast-enhanced ultrasonography with intraperitoneal injection of Sonazoid. J Gastroenterol Hepatol. 2010;25(2):383–386.